Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Regeneron Pharmaceuticals
(NQ:
REGN
)
990.68
-7.55 (-0.76%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Regeneron Pharmaceuticals
< Previous
1
2
...
10
11
12
13
14
15
16
17
18
...
40
41
Next >
$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today
September 18, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 15, 2023
September 15, 2023
Via
Benzinga
Peering Into Regeneron Pharmaceuticals's Recent Short Interest
September 14, 2023
Via
Benzinga
Check Out What Whales Are Doing With REGN
September 08, 2023
Via
Benzinga
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is a Leading Gainer in 9/8 Morning Trading
September 08, 2023
Via
Investor Brand Network
If You Invested $100 In This Stock 20 Years Ago, You Would Have $4,000 Today
September 05, 2023
Via
Benzinga
AI Integration In Biotech & Pharma: Companies Positioned To Benefit
September 11, 2023
The convergence of artificial intelligence (AI) with the biotech and pharmaceutical sectors is ushering in a new era of innovation. AI is catalyzing transformations from drug discovery to patient care....
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
New to Investing? Here's How You Can Get Started With $500.
September 10, 2023
You don't have to invest a lot to start building a winning portfolio.
Via
The Motley Fool
3 Unstoppable Growth Stocks to Buy Right Now
September 09, 2023
These healthcare stocks show no signs of slowing down.
Via
The Motley Fool
Regeneron Provides Update on Planned Chief Financial Officer Transition
September 08, 2023
Robert E. Landry to retire effective February 2024; Christopher Fenimore, long-standing Senior Vice President, Head of Accounting and Controller, to assume CFO role
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Looking At Regeneron Pharmaceuticals's Recent Unusual Options Activity
August 30, 2023
Via
Benzinga
Check Out What Whales Are Doing With REGN
August 25, 2023
Via
Benzinga
Is Regeneron Stock a Buy Now?
August 25, 2023
The company's growth fuel isn't running out yet.
Via
The Motley Fool
Regeneron Announces Updates to Board of Directors
September 08, 2023
Kathryn Guarini, Ph.D., and David P. Schenkein, M.D., join Regeneron’s Board of Directors
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
2 Top Biotech Stocks to Buy in September
September 08, 2023
There is rarely a bad time to buy stocks with massive upside potential.
Via
The Motley Fool
Could This Biosimilar Drug Be Novartis' Next Blockbuster?
September 05, 2023
Novartis expects to submit regulatory applications for its biosimilar soon.
Via
The Motley Fool
Is REGENERON PHARMACEUTICALS (NASDAQ:REGN) suited for quality investing?
September 01, 2023
This article explores why quality investors may have a look at REGENERON PHARMACEUTICALS (NASDAQ:REGN)
Via
Chartmill
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Acer Therapeutics Inc. (Nasdaq - ACER), Sovos Brands, Inc. (Nasdaq - SOVO), Computer Task Group, Incorporated (Nasdaq - CTG), Decibel Therapeutics, Inc. (Nasdaq -
August 31, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
Peering Into Regeneron Pharmaceuticals's Recent Short Interest
August 22, 2023
Via
Benzinga
Small Cancer Therapy Player Celularity To Provide Research Support For Regeneron's Therapy
August 29, 2023
Celularity Inc (NASDAQ: CELU) shares are trading higher after the company announced a multi-year Research Collaboration Services Agreement with Regeneron Pharmaceuticals Inc (NASDAQ: REGN).
Via
Benzinga
Wall Street Thinks This Tiny Biotech Company Could Soar Soon
August 28, 2023
An upcoming regulatory decision could prove to be an inflection point in the biotech's life cycle.
Via
The Motley Fool
These Are the ONLY 7 Penny Stocks to Consider in August 2023
August 26, 2023
These are just a few of the most promising penny stocks to consider as we head into the final months of the year.
Via
InvestorPlace
Regeneron Announces Investor Conference Presentations
August 23, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Could This Medicine Be the Next Winner for Novartis?
August 23, 2023
The Swiss drugmaker recently reported that a drug candidate met the primary endpoints in phase 3 clinical trials.
Via
The Motley Fool
Top 5 Health Care Stocks That May Fall Off A Cliff
August 23, 2023
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.
Via
Benzinga
Regeneron Awarded $326M Government Contract For COVID-19 Antibody Therapy Development
August 22, 2023
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) was awarded a government contract valued at up to $326 million on Tuesday.
Via
Benzinga
Exposures
COVID-19
Regeneron Announces Agreement with BARDA Supporting Development of Next-Generation Antibody Therapy for COVID-19 Prevention
August 22, 2023
Program is part of U.S. Government’s ‘Project NextGen’ and provides partial funding for clinical development of a novel monoclonal antibody therapy
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron's Crucial Eylea HD Approval: A Shield Against Potential Biosimilar Competition?
August 21, 2023
Friday, the FDA approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) approved Eylea HD (aflibercept) Injection 8 mg for wet age-related macular degeneration, diabetic macular edema,
Via
Benzinga
Exposures
Product Safety
Value Stocks Outshine Growth Amidst Rising Treasury Yields: Key Sectors and Stocks Analyzed
August 21, 2023
The Vanguard Value Index Fund ETF (ARCA: VTV) has beaten the Vanguard Growth Index Fund ETF (ARCA: VUG) by 5% during the past month. The momentum shift comes as investors recalibrate their strategies...
Via
Benzinga
Topics
ETFs
Large Cap Biopharmaceuticals Performance 2023 YTD: Mixed Results But Lilly Is A Big Winner
August 21, 2023
Biotech stocks are in a bear market since the IBB hit $177.37 in 2021 and is down 7.84% over five years.
Via
Talk Markets
< Previous
1
2
...
10
11
12
13
14
15
16
17
18
...
40
41
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.